Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
Niklas Gremke(Philipps University of Marburg), Thorsten Stiewe(Philipps University of Marburg), Anne‐Sophie Litmeyer(Universitätsklinikum Gießen und Marburg), Thomas Karn(Goethe University Frankfurt), Paul Jank(Universitätsklinikum Gießen und Marburg), Martin F. Fromm(Friedrich-Alexander-Universität Erlangen-Nürnberg), Carsten Denkert(Universitätsklinikum Gießen und Marburg), Sabrina Elmshäuser(German Center for Lung Research), Mattea Reinisch(University of Mannheim), Sabine Schmatloch, Nader Hirmas(German Breast group), Thomas Wündisch, Uwe Wagner(German Society of Surgery), R. Verena Taudte(Philipps University of Marburg), Michael Wanzel(German Center for Lung Research), Isabelle Besong(Universitätsklinikum Gießen und Marburg), Luise von Wichert(Universitätsklinikum Gießen und Marburg), Marie Witt(Universitätsklinikum Gießen und Marburg), S. Loibl(German Breast group), Sebastian Griewing(Philipps University of Marburg)
Cited by 19
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
|Breast Cancer Research and Treatment|2007|297
Induction and down-regulation of PLK, a humanserine/threonine kinase expressed in proliferating cells andtumors.
|Proceedings of the National Academy of Sciences|1994|283
PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor
|Proceedings of the National Academy of Sciences|1998|202